CORDIS provides links to public deliverables and publications of HORIZON projects.
Links to deliverables and publications from FP7 projects, as well as links to some specific result types such as dataset and software, are dynamically retrieved from OpenAIRE .
Deliverables
Research data will be managed mainly by myself with the support of Dr. Ablain. Inserm, one of CRCL’s head institutions, has implemented a secure electronic notebook system that we will use on a daily basis to record experimental details, report results and keep track of my progress on each task of the experimental plan. The data will be available to Dr. Ablain and access to all or part of it will be granted to other people involved in the project (collaborators, core facility personnel, members of the Ablain team) in accordance with the FAIR principles (Findable, Accessible, Interoperable, Reusable) of data acquisition, management and reporting. In addition, if some of the data (especially from task 1.2) may lead to the development of products (e.g. small molecule inhibitors or blocking antibodies) or therapeutic applications against melanoma or other cancers, we will take protection measures and evaluate the opportunity to file patents with the help of Inserm Transfert, an office dedicated to the translation of findings from basic research into commercial products or clinical applications. Moreover, we will make our scRNA-seq data on human melanoma available on public data repositories such as GEO as soon as it is processed.
During this project I expect to generate results which will be of interest to a variety of target audiences and thus will be made publicly available through dissemination. Results are as follows: 1) Generation of scRNA-seq data to identify melanoma cell/niche interactions. This will constitute an invaluable resource for cancer researchers. The raw data will be made available on a public data repository and its analysis may lead to the submission of a manuscript. 2) Novel method to establish reconstructed skin models. This will be of considerable interest to both academia and industry as a powerful tool for mechanistic investigation and drug testing. It will be described in a methods paper. 3) Identification of potential drug targets for the development of therapeutics against disseminated melanoma cells. These results will be reported in a publication and may initiate a collaboration with the C3D drug discovery platform and/or Inserm Transfert and/or industry partners. They may be of great interest to pharmaceutical and biotech companies but dissemination will depend on IP protection measures. However, they will be disseminated to the general public, patients and funding agencies in a simplified form. 4) Functional study of the impact of cancer/niche cell interactions. These results will be of interest to the cancer research community. The main project findings will be disseminated through presentations at conferences relevant to the cancer, metastasis or zebrafish fields and other local seminars.To reach the general public and patients with cancer, I will present the results of my research in non-specialist terms at the yearly conference organised by the Ligue Contre le Cancer foundation and that gathers various groups of people interested in cancer research including patients, students, biotech and pharmaceutical companies, clinicians and academics. I will also contribute to the monthly newsletter of the CLB (CRCL’s associated hospital) to keep local clinicians and patients informed of our progress. Finally, I will post science updates on social network platforms like LinkedIn and Twitter on a monthly basis.
Searching for OpenAIRE data...
There was an error trying to search data from OpenAIRE
No results available